Vir's Monthly Hepatitis Delta Combo Clears Its First Phase 3
- Vir's once-monthly elebsiran (siRNA) plus tobevibart (antibody) met the primary endpoint in the Phase 3 ECLIPSE 1 trial in chronic hepatitis delta, versus delayed treatment.
- The primary endpoint required both undetectable HDV RNA and normalized ALT at week 48; 44% of treated patients reached it.
- Safety looked clean, with no discontinuations, and a US filing is planned for mid-2027.
💡 Points Based on public reports
The control was a delayed-treatment arm, a comparison that says little about how the regimen stacks up against bulevirtide, the only approved option in Europe. The head-to-head and switch studies due next year decide the commercial story against Gilead and Mirum. Monthly dosing is a genuine convenience edge if durability holds off treatment.
Vir says hepatitis D drug combination succeeds in first pivotal study ↗